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Abstract
Background. Hepatic resection is the standard treatment for colorectal liver metastases when feasible. Techniques such as
radiofrequency ablation (RFA) have been the subject of ongoing research in hopes of achieving a similar survival to that
achieved with hepatic resection, but with less morbidity and better quality of life (QOL). The aim was to to generate a
hypothesis concerning the cost-utility of various treatments that may be further tested with randomized trials in the
future. Patients and methods. This was a prospective, non-randomized pilot study comparing the cost-utility of hepatic
resection, RFA, systemic chemotherapy, and symptom control alone for colorectal liver metastases. All patients with newly
diagnosed liver malignancies were eligible. QOL was measured serially with the Health Utilities Index. Costs, in 2001
Canadian dollars, were captured from the viewpoint of society in general. Results. In all, 40 patients were enrolled in the
study: 7 underwent hepatic resection, 7 underwent RFA (sometimes in combination with resection), 20 received systemic
chemotherapy, and 6 received symptom control alone. Liver resection appeared to be the most effective approach, with an
average benefit of 2.58 QALYs (quality-adjusted life years) compared with 1.95 QALYs for RFA, 1.18 QALYs for
chemotherapy, and 0.82 QALYs for symptom control alone, resulting in cost-utility ratios of $7792, $8056, $12 571, and
$4788 per QALY, respectively. Discussion. The cost-utility of hepatic resection and RFA appeared similar even though
patients receiving RFA had more advanced disease. The role of RFA is still being defined; however, if long-term survival
proves to be promising, then this study lends support to the conduct of randomized controlled trials in the future.
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Introduction
Unfortunately, among all patients with metastatic
liver disease only a small fraction will be candidates
for curative resection [1,2], which currently offers the
best chance for long-term survival [3,4]. The compli-
cations of surgical resection are significant, however
[5]. Newer chemotherapeutic agents may offer med-
ian survival rates up to 20 months [6], but long-term
survival is rare. Regional techniques such as radio-
frequency ablation (RFA) have been the subject of
ongoing research in hopes of achieving a similar
survival to hepatic resection, but with less morbidity
and better quality of life (QOL) [4,7]. Presently, RFA
is indicated for patients with tumors that are unre-
sectable on the basis of multifocal disease, poor liver
reserve, proximity to major vascular structures, or
poor overall medical condition [8]. Longer follow-up
is needed before firm conclusions can be made about
the effectiveness of RFA.
With limited resources available to healthcare
systems, the costs of a particular treatment and the
QOL gained survival are also important in decision-
making. To date, only a few studies have evaluated the
cost-utility of treatments for liver malignancies, none
of which have been performed within the context of
the Canadian healthcare system. QOL after treat-
ments for liver metastases is not well described in
clinical studies and patients must often rely mainly on
anecdotal information.
The present study was undertaken to describe the
costs and QOL associated with the different treat-
ments available for colorectal liver metastases.
Although the initial results of RFA appear promising,
this technique is still relatively new. If the long-term
survival proves similar to that of hepatic resection,
then perhaps randomized controlled trials would be
justified in the future. The present study was designed
to explore a hypothesis that the cost-utility of RFA
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and hepatic resection might be similar enough to
justify such a trial. Systemic chemotherapy and
symptom control alone (i.e. palliative treatment)
were included in the study because the costs and
QOL after all treatments for liver metastases are
poorly described and the cost-utility of all treatment
options should be within an acceptable range [9] if
physicians are to continue to recommend them.
Patients and methods
Study design
This study was a cost-utility analysis comparing
surgical resection, RFA, systemic chemotherapy, and
symptom control alone (palliative care) for the treat-
ment of malignant liver tumors. The study was purely
descriptive and did not influence the treatment
received by the patients in any way. The protocol
was approved by the University of Manitoba’s Health
Research Ethics Board.
Patient selection
The primary focus of the study was patients with
CRC liver metastases; however, patients with any
hepatic malignancy were considered eligible. Patients
with liver tumors other than colorectal metastases
were considered eligible in order to boost the sample
sizes and to allow this pilot study to better explore a
hypothesis regarding the cost-utility of liver resection
and RFA. These patients were considered eligible
because the costs of treatment and the QOL over the
time-frame of this study were not expected to be
significantly different from those with colorectal
metastases. The survival data for these patients were
not included in the analysis (see below). All new
patients referred to a medical oncology department or
to a hepatobiliary surgeon (M.T.) between June 2001
and December 2002 were eligible.
Treatment and follow-up
Patients determined which treatments they wished to
pursue based on their physicians’ best clinical judg-
ment and the patients’ wishes and then informed
consent was obtained. Patients were followed up to
2 years after enrolment or until the end of the study
period (September 2003).
Patients undergoing either surgical resection or RFA
were treated by a single surgeon (M.T.). All patients
who underwent laparotomy had a preoperative mag-
netic resonance imaging (MRI) scan in addition to a
computed tomography (CT) scan and any other
imaging that was done. Patients who were candidates
for liver resection were offered the procedure. RFA
was offered to patients who were still operative
candidates, but had disease that was considered
unresectable on the basis of multifocal disease, proxi-
mity to major vascular structures, poor liver reserve, or
poor overall medical condition. RFA was performed
using the RF 3000† Radiofrequency Ablation System
(Boston Scientific) at the time of open laparotomy
with real-time intraoperative ultrasound (IOUS) gui-
dance. These patients were also considered for adju-
vant chemotherapy at the discretion of the medical
oncologists. Patients undergoing chemotherapy were
assigned to receive one of four chemotherapeutic
regimens at the discretion of the treating oncologist:
single agent irinotecan, 5-fluorouracil (5-FU) and
leucovorin (LV), irinotecan plus 5-FU and LV, or
single agent capecitabine.
Cost-utility analysis
This paper has followed the recommendations of the
US Panel on Cost-Effectiveness in Health and Med-
icine [1012]. QOL was measured by the Health
Utilities Index Mark II (HUI2) and Mark III (HUI3),
although the HUI3 was used primarily in the cost-
utility analysis. The questionnaire was administered
to the participants at entry into the study and then at
2 weeks, 3 months, 6 months, 9 months, 12 months,
and 18 months after commencing treatment.
Costs (not hospital charges) were measured from
the perspective of society as a whole in 2001 Canadian
dollars and included the medical resources consumed,
the non-medical resources consumed, and the loss of
productivity associated with illness or disability. (The
term ‘productivity costs’ has been suggested to refer
to these costs [11,13].) Inpatient costs were captured
by the hospital’s cost-accounting system [14]. Costs
from the operating room (OR) were acquired by
prospectively tracking the resources consumed in the
OR during each case. Overhead costs were calculated
to be 16.5% of the total variable hospital costs, based
on a previous publication [15]. Costs of delivering
chemotherapy were calculated using a case-mix group
approach, by calculating the cost of a cycle of each
chemotherapeutic regimen and then measuring the
costs for each patient based on the number of cycles of
the particular chemotherapy regimens received. The
cost of blood products was taken from another study
[16] and adjusted to 2001 dollars [17]. Costs paid by
patients and caregivers including time spent seeking
and receiving treatment, travel costs, and drug costs
were recorded by patients in diaries that were
collected at follow-up visits.
A cost-utility analysis was performed by creating a
Markov decision analysis model (see Figure 1) using
the computer software Data 3.5# (Treeage Software,
Inc., 1999). The time-frame of the analysis was 5
years. Survival data were taken from existing literature
since the numbers in the current study were small,
and then converted to quality-adjusted life years
(QALYs) using the utility scores. The annual inflation
rate used in the baseline analysis was 1.96% [18] and
the discount rate was 3% [11,13].
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Statistical analysis
The sample was one of convenience. Formal power
calculations were not performed because this study
was not designed to draw firm conclusions, but to
develop hypothesis data. Continuous variables were
analyzed with the Mann-Whitney U test. For cate-
gorical variables, the Fisher’s exact test was used.
When testing for differences in QOL over time,
repeated measures ANOVA was used. Statistical
significance was defined using p/0.05. The statis-
tical analysis was performed using SPSS† Base 14.0
for Windows†.
Results
Patient characteristics
Forty patients were recruited: 7 underwent hepatic
resection, 7 underwent RFA (4 had RFA in combina-
tion with resection), 20 received systemic chemother-
apy, and 6 received symptom control alone. Patient
characteristics are shown in Table I, and the char-
acteristics of the patients undergoing surgical treat-
ments (resection and RFA) are shown in Tables II
and III. Patient characteristics were generally similar
between groups in terms of age, gender, and types
of tumors, with no significant differences. Patients
who underwent RFA had a greater number of liver
lesions than patients who underwent liver resection
(pB/0.01). Patients who received chemotherapy as the
primary treatment had more lesions than patients
receiving other treatments (pB/0.05).
Treatment and follow-up
Unfortunately, several patients either withdrew or
were lost to follow-up. One patient who underwent
resection (1 of 7), one patient who received RFA (1 of
7), three patients who received chemotherapy (3 of
20), and three who elected to receive symptom
control alone (3 of 6) were either lost to follow-up
or withdrew from the study.
For the majority of patients who underwent surgical
procedures, the planned procedure was performed.
Three patients who underwent hepatic resection,
three patients who underwent RFA, and two patients
who initially decided to receive symptom control
alone also received systemic chemotherapy. Three
patients in the group receiving chemotherapy as
the primary treatment had an initial exploratory
Figure 1. Representation of Markov decision model in the format used by Data 3.5#.
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laparotomy with the intent to perform hepatic resec-
tion or RFA, but exploration and intraoperative
ultrasound (IOUS) found inoperable disease that
was not detected on preoperative imaging. These
costs were included in the analysis.
Cost-utility analysis
Survival data were taken from existing literature. For
resection of colorectal liver metastases, a recent review
of all large case series reported a 5-year survival of
34% and a mortality rate of 3.3% [5]. For RFA, only
one study has so far reported 5-year survival (30%)
[19]. The simple averages of the 1-, 2-, and 3-year
survival figures from other available series are 90.2%,
66.5%, and 48.3%, respectively [1926]. The mean
of reported mortality rates from two large series was
0.8% [27,28]. For systemic chemotherapy, the survi-
val data used in the analysis were taken from two
recent randomized controlled trials (RCTs) involving
irinotecan, 5-FU, and leucovorin, where the median
survival was 14.8 months to 17.4 months [29,30].
The survival beyond 1 year was modeled, using a
logarithmic survival curve. For symptom control
alone, the survival data for this group of patients
came from previously published studies [3137].
Simple averages of the reported survival rates for ‘all
comers’ at 1, 2, 3, and 5 years are 31%, 10%, 3%, and
1%, respectively.
The initial costs for patients who underwent hep-
atic resection or RFA were similar (Tables IV and V).
Surgeons’ fees and anesthesiologists’ fees were
included in the OR costs, while the radiologists’
fees were included in the costs of the diagnostic
imaging.
The average initial treatment costs for patients
receiving systemic chemotherapy and for patients
receiving symptom control alone were $439 and
$500, respectively. These costs included the costs of
the initial consultation, the costs involved in the
diagnostic work-up, and the costs associated with
exploratory laparotomy. The cost of receiving che-
motherapy for all patients was entered into the cost-
utility model as a function of time (Table VI).
QOL is shown in Figure 2. For patients who
underwent surgical treatments (hepatic resection or
RFA) QOL scores decreased for the first few months
postoperatively. The health attribute of pain was
largely responsible for this postoperative decrease in
QOL. Overall and marginal cost-utility ratios are
presented in Figures 3 and 4.
Sensitivity analysis showed that the results were
sensitive to the magnitude of the utility scores, the
survival associated with each treatment, and the costs
of hepatic resection, RFA, and chemotherapy.
However, over a wide range of values, uncertainty in
these costs and effects changed the magnitudes of the
cost-utility ratios, but not the relative ranking of the
treatments.
Discussion
There are many limitations to the present study, since
it was not designed to draw firm conclusions, but to
explore a hypothesis that the cost-utilities of hepatic
resection and RFA might be similar enough to one
day justify a randomized trial. The accrual rate was
lower than anticipated and the sample size is small.
The study compared patients with different stages of
disease, since patients with resectable disease were
offered surgery. Patients receiving chemotherapy
seemed to have the most advanced disease. Those
receiving RFA were considered to have unresectable
disease and had significantly more lesions than the
patients undergoing hepatic resection. RFA was
sometimes used in combination with resection to
Table I. Characteristics of overall study population.
Category Overall Resection RFA Chemotherapy Palliative care
n 40 7 7 20 6
Age Mean 64.4 66.6 57.9 63.4 73.2
SD 11.1 10.8 12.1 11.3 4.7
Male:female Male 29 6 5 12 6
Female 11 1 2 8 0
No. of lesions* 5/3 19 7 3 4 5
/3 19 0 4 14 1
Tumour type* Colorectal 32 5 6 17 4
Other 8 2 1 3 2
Time of metastases* Synchronous 17 3 4 7 3
Metachronous 18 4 2 10 2
Extrahepatic disease* Yes 7 0 1 4 2
No 30 7 6 14 3
ASA score* Value 2.61 2.71 2.43 2.70 3.00
n 28 7 7 10 2
*For some categories, information was not available for all patients.
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Table III. Characteristics of patients undergoing radiofrequency ablation (RFA).
Gender
Age
(years)
Tumour
type
No. of liver
lesions
Timing of
lesion Location
Extrahepatic
disease Treatment Chemotherapy
Comorbid
disease
ASA
score
F 42 Rectal 4 Synchronous Right lobe Yes RFA No Nil 2
F 77 Rectal 2 Metachronous Left/right lobes No Resection & RFA No DM II, HTN, breast CA 3
M 63 Colon 2 Synchronous Left/right lobes No Resection & RFA Yes HTN 2
M 64 Rectal 4 Synchronous Left/right lobes No Resection & RFA Yes DM II 2
M 50 HCC 1 NA Right lobe No RFA No HCV, HTN, DMII 3
M 60 Rectal 4 Metachronous Left/right lobes No Resection & RFA No Nil 3
M 49 Colon 4 Synchronous Right lobe No RFA Yes Nil 2
DM II, type II diabetes mellitus; HTN, hypertension; HCV, hepatitis C virus.
Table II. Characteristics of patients undergoing hepatic resection.
Gender
Age
(years)
Tumor
type
No. of liver
lesions
Timing of
lesion Location
Extrahepatic
disease
Type of
resection Chemotherapy
Comorbid
disease
ASA
score
M 61 Rectal 1 Metachronous Right lobe
(segment 6)
No Wedge No COPD 3
M 72 GIST 1 Metachronous Right lobe (segment 8) No Wedge Yes DM II 2
M 61 Colon 1 Synchronous Left lobe (segment 2) No Wedge Yes COPD, obesity 3
M 48 Testicular 1 Synchronous Right lobe No Right lobe Yes HTN 3
M 74 Colon 1 Synchronous Right lobe No Wedge No HTN 3
M 69 Rectal 1 Metachronous Right lobe No Wedge No HTN, DM II 2
F 81 Colon 1 Metachronous Left lobe No Wedge No Nil 3
COPD, chronic obstructive pulmonary disease; DM II, type II diabetes mellitus; HTN, hypertension.
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extend the capabilities of surgical resection. Patients
who underwent a combination of RFA and liver
resection were grouped with patients who underwent
RFA alone, since it was hypothesized that RFA would
be less effective than hepatic resection and that the
effectiveness of RFA would be the major determinant
of survival. Patients with non-colorectal cancers were
included since the costs of their treatments and their
QOL afterwards were expected to be reasonably
similar to those with colorectal cancers and would
help explore the hypothesis of the study.
In cost-effectiveness analysis, not every variable
must be measured with absolute certainty [13]. Error
in certain measurements may not influence the overall
results. It may be more important to obtain a reason-
able range of values and then test the influence of this
uncertainty and the robustness of the conclusions
with a sensitivity analysis. The most robust conclu-
sions are those that hold true over a wide range of
values. The sensitivity analyses in this study showed
that uncertainty in these costs and effects would
change the magnitudes of the cost-utility ratios, but
not the overall rankings of the treatments and the
general conclusions.
The QOL measured in this study appears accurate,
as it is consistent with measurements by others [38].
Patients who underwent hepatic resection and RFA
had quite good long-term QOL. In the period shortly
after surgery these scores dropped, mainly due to
postoperative pain, but after 36 months the scores
returned to baseline or higher for most patients. QOL
in patients treated with systemic chemotherapy re-
mained reasonably high for the first 12 months of
treatment. Disease invariably progresses with systemic
chemotherapy, and this is the likely explanation for
the eventual decline. The patients who elected to
receive symptom control alone had quite high utility
scores, suggesting that the absence of treatment-
related side effects may be important, although a
third of these patients did choose to receive che-
motherapy during the course of their disease.
To put these scores into a clinical perspective, the
mean HUI3 utility scores for people considered to be
in good health and without chronic medical condi-
tions taken from a population-based sample of over
17 000 Canadians was 0.93 [39], and utility for
patients with various chronic conditions ranged from
0.54 to 0.83 [39,40].
The initial costs of hepatic resection and RFA were
similar and there were no significant differences in
mean operating time or hospital stay. The OR costs
found in this study were similar to other Canadian
results [41], again supporting the accuracy of our
results. The costs of hepatic resection and of RFA in
Table IV. Initial hospital costs of treatment for patients undergoing liver resection and RFA.
Resection RFA
Category Average SD Average SD p value
LOS* 7.3 2.0 6.4 1.7 0.60
Nursing $1860.86 $676.50 $1608.77 $456.52 0.66
Lab fees $171.83 $36.61 $128.30 $72.26 0.23
Imaging $324.37 $49.46 $485.81 $134.99 0.09
Medications $115.71 $69.57 $86.48 $67.65 0.34
Other $267.28 $118.07 $156.76 $81.43 B/0.05
OR costs $2907.72 $517.52 $3131.98 $907.65 0.66
Overhead $424.74 $134.12 $370.56 $110.91 0.66
Total $6064.61 $1220.75 $5971.23 $1142.73 0.66
*Length of stay in hospital (measured in days).
Table V. Cost of surgery for patients undergoing hepatic resection and RFA.
Resection RFA
Category Average SD Average SD p value
OR time (min) 291 77 279 61 0.70
OR staffing $477.68 $126.26 $457.54 $99.90 0.70
Supply costs $549.98 $181.89 $1107.10 $833.15 0.14
PARR costs* $58.96 $21.91 $53.30 $15.49 0.75
Overhead $179.29 $40.62 $304.25 $235.96 0.28
MD fees$ $1641.81 $324.23 $1553.80 $211.71 0.48
Total $2907.72 $517.52 $3131.98 $907.75 0.85
*Post anesthesia recovery room costs.
$MD fees include the fees paid to the surgeons and to the anesthetists.
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the Canadian setting are much lower than reported
from American studies ($23 317 US dollars in 1998
for liver resection) [42,43], likely reflecting funda-
mental differences in the healthcare systems. Thus,
caution must be used when applying the economic
data of this study to other healthcare systems (and
vice versa).
In this study, RFA was done through a laparotomy.
The costs of percutaneous RFA would probably be
lower, but there are several reasons as to why this was
not done in the current study. Four patients under-
went RFA in conjunction with hepatic resection in
order to expand the capabilities of resection alone.
These patients would have needed a laparotomy
regardless. Another reason is that the sensitivity of
IOUS is higher than that of other preoperative
imaging modalities to detect hepatic lesions. IOUS
has been shown to alter decision-making in the
operating room in 1844% of cases [4446]. Elias
et al. found unsuspected metastases in 41% of
patients who underwent hepatectomy for CRC liver
metastases that would not have been treated with
percutaneous techniques [47]. Another advantage of
an open surgical approach is the ability to occlude
hepatic inflow when tumors are adjacent to major
vascular structures to increase the likelihood of
complete tumor necrosis [7]. Tumors abutting the
diaphragm are not always amenable to a percutaneous
approach [7]. If patients were to undergo RFA in the
outpatient setting, we would anticipate a significant
difference between the cost of resection and RFA,
although it is possible that the effectiveness would
suffer.
The costs of chemotherapy were considerable, even
in patients undergoing surgical procedures. Because
treatment of cancer involves a multidisciplinary ap-
proach with specialists from different backgrounds, it
was felt that the costs of providing chemotherapy to
patients undergoing surgery or symptom control
should be included in the analysis, as this approx-
imates what is done in clinical practice. If the benefits
of adjuvant treatment are included, the costs should
be as well.
Another shortcoming of this study is that subse-
quent hospitalizations for disease recurrence or treat-
ment complications may have occurred in other
hospitals or after the study period ended. The costs
of these hospitalizations would not have been cap-
tured.
The cost-utility of hepatic resection and radio-
frequency ablation appear similar. Resection appeared
to offer a greater quality-adjusted survival than RFA,
Figure 2. Health Utilities Mark III scores for all treatments.
Table VI. Costs for chemotherapy in patients undergoing other primary treatment modalities.
Treatment
No. receiving
chemotherapy
Months until
chemotherapy
started
Months until
chemotherapy
stopped
Average total
cost
No. of months
treated
Cost per
month*
Resection 3 of 7 9.7 5.0 $6008.19 5.0 $1003.72
RFA 3 of 7 3.7 9.3 $17 842.87 9.3 $830.89
Chemotherapy 20 of 20 0.5 11.2 $21 581.45 11.2 $1979.27
Palliative care 2 of 6 4.0 5.3 $1020.97 5.3 $478.22
*Cost per month refers to the cost per month for those months when chemotherapy was given. These costs were inputted into the cost-
utility model only for the average period of time when patients received their chemotherapy.
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but at a higher cost. In addition to overall cost-utility,
the marginal cost-utility is important when deciding
between alternative treatments. Marginal cost-utility
refers to the incremental difference in cost and in
effectiveness between two alternative treatments,
rather than a simple comparison of the overall cost-
utilities. Compared to symptom control alone, sys-
temic chemotherapy had a marginal cost-utility ratio
of $30 537 per QALY. RFA offered a greater number
of QALYs than chemotherapy at only a slightly
increased cost, yielding a very favorable marginal
cost-utility of $858 per QALY. Hepatic resection
had a marginal cost-utility ratio of $6974 per QALY
compared to RFA, which is again quite favorable [9].
Hepatic resection demonstrated a marginal cost-
utility ratio of $3609 per QALY compared to systemic
chemotherapy.
The US Panel recommends that health conse-
quences be measured with generic health-state classi-
fication systems that express QOL in terms of utilities
that are based on community preferences, and that
the utility measurements can then be converted to
QALYs [11]. The Health Utilities Index was chosen
for this study since it fulfils these criteria [4850].
Another advantage of describing QOL with utility
scores is that it allows comparisons across diseases
and between studies [11].
Another major assumption necessitated by the
limited follow-up period was that the QOL scores
for patients surviving longer than 2 years were
assumed to be stable after the last measurement at
18 months. The HUI scores were composed of
patients who were recurrence-free, patients experien-
cing recurrence, and patients experiencing side effects
of the treatments. Thus, these scores would likely
reflect the effects of disease recurrence in the future
beyond the time-frame of the study.
The purpose of this study was not to draw firm
conclusions comparing these treatment options for
liver metastases from colorectal cancer, but to explore
a hypothesis regarding the feasibility of future com-
parisons of RFA to hepatic resection. Even with
supporting evidence that the cost-utilities may be
similar, the long-term survival associated with RFA is
still largely unknown and would need to be evaluated
before a randomized trial could ethically be carried
out. Because RFA cannot be considered an equivalent
treatment to liver resection at present, the existing
trials have consisted of patients with unresectable
disease. In spite of this, some early studies have
reported survival similar to that of resection [21
23]. Others have been less enthusiastic [25], so
longer-term follow-up is essential.
Conclusions
The QOL associated with both hepatic resection and
RFA appears quite good, and the cost-utility of hepatic
resection and RFA for colorectal liver metastases
appears similar. The cost-utility ratio of systemic
chemotherapy is higher, but still well within the range
of what is considered to be medically and economically
acceptable [9]. Should the long-term survival benefit
of RFA prove to be close to that of hepatic resection,
this study would offer support for a randomized trial
comparing the two treatments in the future.
Figure 4. Marginal cost-utility ratios of available treatments for malignant liver tumours using HUI3 data. The marginal cost-utility ratios
are given for the next most effective treatment in each case. The marginal cost-utility ratio of chemotherapy is compared to symptom
control alone; the marginal cost-utility ratio of RFA is compared to chemotherapy; and the marginal cost-utility ratio of hepatic resection is
compared to RFA.
Figure 3. Overall cost-utility ratios of available treatments for malignant liver tumors using HUI3 data.
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